Recent Posts
- Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
- Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
- Elutia Regains Compliance with Nasdaq Listing Requirements
- Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
- Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results